A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
PURPOSE: Survival rates of patients with high-risk neuroblastoma are unacceptable. A time-intensified treatment strategy with delayed local treatment to control systemic diseases has been developed in Japan. We conducted a nationwide, prospective, single-arm clinical trial with delayed local treatment. This study evaluated the safety and efficacy of delayed surgery to increase treatment intensity. PATIENTS AND METHODS: Seventy-five patients with high-risk neuroblastoma were enrolled in this study between May 2011 and September 2015. Delayed local treatment consisted of five courses of induction chemotherapy (cisplatin, pirarubicin, vincristine, and cyclophosphamide) and myeloablative high-dose chemotherapy (melphalan, etoposide, and carboplatin), followed by local tumor extirpation with surgery and irradiation. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS), response rate, adverse events, and surgical complications. RESULTS: Seventy-five patients were enrolled, and 64 were evaluable (stage 3, n = 8; stage 4, n = 56). The estimated 3-year PFS and OS rates (95% confidence interval [CI]) were 44.4% [31.8%-56.3%] and 80.7% [68.5%-88.5%], resspectively. The response rate of INRC after completion of the treatment protocol was 66% (42/64; 95% CI: 53%-77%; 23 CR [complete response], 10 VGPR [very good partial response], and nine PR [partial response]). None of the patients died during the protocol treatment or within 30 days of completion. Grade 4 adverse effects, excluding hematological adverse effects, occurred in 48% of patients [31/64; 95% CI: 36%-61%]. Major Surgical complications were observed in 25% of patients [13/51; 95% CI: 14%-40%]. CONCLUSION: This study indicates that delayed local treatment is feasible and shows promising efficacy, suggesting that this treatment should be considered further in a comparative study of high-risk neuroblastoma.
Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event‐free survival in patients with high‐risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746‐755.
Ikeda H, Iehara T, Tsuchida Y, et al. Experience with International Neuroblastoma Staging System and Pathology Classification. Br J Cancer. 2002;86(7):1110‐1116.
Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002;24(8):613‐621.
Kawa K, Ohnuma N, Kaneko M, et al. Long‐term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease‐free for more than 66 months. J Clin Oncol. 1999;17(10):3216‐3220.
Ohnuma N, Takahashi H, Kaneko M, et al. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol. 1995;24(3):181‐187.
Suita S, Tajiri T, Kaneko M, et al. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. J Pediatr Surg. 2007;42(3):489‐493.
Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123)I‐metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102(9):1319‐1326.
Vo KT, DuBois SG, Neuhaus J, et al. Pattern and predictors of sites of relapse in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022;69(9):e29616.
Yu AL, Gilman AL, Ozkaynak MF, et al. Long‐term follow‐up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high‐risk neuroblastoma: COG study ANBL0032. Clin Cancer Res. 2021;27(8):2179‐2189.
Hara J, Nitani C, Shichino H, et al. Outcome of children with relapsed high‐risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. Jpn J Clin Oncol. 2022;52(5):486‐492.
Hashii Y, Kusafuka T, Ohta H, et al. A case series of children with high‐risk metastatic neuroblastoma treated with a novel treatment strategy consisting of postponed primary surgery until the end of systemic chemotherapy including high‐dose chemotherapy. Pediatr Hematol Oncol. 2008;25(5):439‐450.
Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86(2):364‐372.
Hishiki T, Matsumoto K, Ohira M, et al. Results of a phase II trial for high‐risk neuroblastoma treatment protocol JN‐H‐07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol. 2018;23(5):965‐973.
Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466‐1477.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205‐216.
Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem‐cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high‐risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(9):649‐658.
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high‐risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13‐cis‐retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165‐1173.
Holmes K, Potschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high‐risk neuroblastoma: a report from the HR‐NBL1/SIOPEN Study. J Clin Oncol. 2020;38(25):2902‐2915.
Pinkerton CR, Zucker JM, Hartmann O, et al. Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group. Br J Cancer. 1990;62(2):319‐323.
von Allmen D, Davidoff AM, London WB, et al. Impact of extent of resection on local control and survival in patients from the COG A3973 study with high‐risk neuroblastoma. J Clin Oncol. 2017;35(2):208‐216.
Simon T, Haberle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013;31(6):752‐758.
Grants
#21ck0106XXXh000X/Japan Agency for Medical Research and Developement
#19ck0106332h0003/Japan Agency for Medical Research and Developement
#21ck0106506h0003/Japan Agency for Medical Research and Developement
